GSK posted higher profit as sales for its specialty treatments for HIV, cancer and asthma beat expectations, offsetting lower ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

A panelist discusses how the HIV patient population has aged significantly, with the average age in their clinic now ...

A Georgia man is facing a felony murder charge after family and prosecutors allege he knowingly did not reveal his ...

Patients in historically redlined neighborhoods experience significantly longer delays in achieving HIV viral suppression ...

The Center in Asbury Park wants people to "Come Early, Stand Proud, and Walk Strong" on May 4 for the New Jersey AIDS Walk ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV medicines.

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

An HIV patient in Laredo is sharing his advice with others living with the disease to raise awareness and highlight available ...

The Trump Administration has gutted many areas of healthcare funding and research, especially in infectious diseases. One ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Dolutegravir is recommended by the World Health Organization (WHO) for infants, children and adults and is the preferred HIV ...